FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | OF CHANGES | S IN BENEFICIAL | OWNERSHIP |
|------------------|------------|-----------------|------------------|

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden

Estimated average burden hours per response: 0.5

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5 |
| obligations may continue. See |
| Instruction 1(h) |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* ENRIGHT PATRICK G | | | 2. <u>J</u> | 2. Issuer Name and Ticker or Trading Symbol Jazz Pharmaceuticals plc [JAZZ] | | | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | |
|---|-----------------------|---|-----------------------------|--|---|------|----------------------------------|--|---|-------------------------|---|---|---|---|--|--|
| (Last) (First) (Middle) CO LONGITUDE CAPITAL PARTNERS LLC | | | | Date of Earliest T 02/15/2013 | Officer (give title Other (specify below) below) | | | | | | | | | | | |
| 800 EL CAMINO REAL, SUITE 220 | | | 4 | . If Amendment, D | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | | | | | | |
| (Street) MENLO PARK CA 94025 | | | | | | | | | X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | | |
| (City) | (St | | | | | | | | | | | | | | | |
| Table I - Non-Deriva | | | | ativ | ve Securities | Acqu | ired, | Disposed of, or Benefic | | | cially Owned | | | | | |
| 1. Title of Security (Instr. 3) | | 2. Transaction Date (Month/Day/Ye | ar) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities A Disposed Of (| Acquired D) (Instr | (A) or . 3, 4 and 5 | 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Direct I Indirect I tr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | Amount | (A) or (D) Price | | | | | | | | |
| Ordinary | ary Shares 02/15/2013 | | 3 | | S | | 18,703(1) | D | \$58.4118 ⁽²⁾ | | 1,599,597 | | | I 1 | By Longitude Venture Partners, L.P. ⁽⁵⁾ | |
| Ordinary Shares | | 02/15/2013 | 3 | | S | | 196(1) | D | \$59.04 ⁽³⁾ | | 1,599,401 | | | I 1 | By Longitude Venture Partners, L.P. ⁽⁵⁾ | |
| Ordinary Shares | | 02/15/2013 | 3 | | S | | 375 ⁽¹⁾ | D | \$58.4124 ⁽²⁾ | | 32,067 | | | I (| By Longitude Capital Associates, L.P. ⁽⁵⁾ | |
| Ordinary Shares | | 02/15/2013 | 3 | | S | | 4(1) | D | \$59.0 | 4 ⁽³⁾ | 32 | ,063 | | I (| By Longitude Capital Associates, L.P. ⁽⁵⁾ | |
| Ordinary Shares | | 02/19/2013 | 3 | | S | | 46,451(1) | D | \$58.1276 ⁽⁴⁾ | | 1,552,950 | | | I 1 | By Longitude Venture Partners, L.P. ⁽⁵⁾ | |
| Ordinary Shares | | 02/19/2013 | 3 | | S | | 921 ⁽¹⁾ | D | \$58.1282(4) | | 31,142 | | | I (| By Longitude Capital Associates, L.P. ⁽⁵⁾ | |
| Ordinary Shares | | | | | | | | | | | | 2,2 | .50 ⁽⁶⁾ | I | D | |
| | | Ta | ble II - Derivat (e.a pi | | Securities Ad , calls, warrar | | | | | | | wned | | | | |
| Derivative Conversion Date Ex Security or Exercise (Month/Day/Year) if a | | 3A. Deemed Execution Date, if any | 4. Tran | 5. Numbor of Derivati Securiti Acquire (A) or Dispose of (D) (Instr. 3, and 5) | 6. Date E Expiration (Month/I | | xercisable and | 7. Tit Amo Secu Unde Deriv | le and unt of rities erlying vative rity (Instr. | 8. De Se (In | Price of rivative curity str. 5) | 9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4) | ly C | .0. Ownership Form: Direct (D) or Indirect I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | | | | | | | | | | | | |

| | | Та | ble II - Deriva (e.g., p | | | | | ired, Disp options, | | | ı or | y Owned | | | |
|---|---|--|---|----------------|---------------------------|-----------------------------|------------------|---------------------------|----------------|----------------------------|--------------------------------------|---------------------------|--|------------------------------|---------------------------------------|
| 1. Title of Derivative | 2. Conversion | 3. Transaction | 3A. Deemed Execution Date, | Code Transa | V | (5A)Nu | ım (150e) r | 6xDatisEbler Expiration D | ist⊋abtlee and | 7itTëtle | aShiodares | 8. Price of Derivative | 9. Number of derivative | 10. Ownership | 11. Nature |
| (Instr. 3) 1. Securities | n of Exespises Price of were sold pursu Derivative | e (Month/Day/Year) lant to a 10b5-1 tradii | if any (Month/Day/Year) ng plan. | Code (8) | Instr. | ^I Secu . Acqı | | (Month/Day/ | Year) | Securi Underl Deriva | ties ying tive | Security (Instr. 5) | Securities Beneficially Owned | Form: Direct (D) or Indirect | Beneficial Ownership (Instr. 4) |
| Pharmaceuti separate pric | cals plc, any sec e within the ran | curity holder of Jazz I ges set forth in this fo | These shares were so Pharmaceuticals plc, cootnote. | or the sta | aff of the | e Disp of (D | pisied an | id Exchange Co | ommission, up | oand ₁ 4): | st, full infor | mation regard | li Reported nber of Transaction(s) | f shares sold at | each |
| (Instr. 4) 3. The price reported is a weighted average price. These shares were sold in multiple transfer gons at prices ranging from \$59.03 to \$59.05, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. | | | | | | | | | | | | | | | |
| 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$58.00 to \$58.34, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. | | | | | | | | | | | | | | | |
| 5. The reporting person disclaims beneficial ownership of the securities of Jazz Pharmaceuticals plc held by Longitude Venture Partners, L. Amount on gitude Capital Associates, L.P., except to the extent of his pecuniary interest therein. 6. These restricted stock units were granted pursuant to Jazz Pharmaceuticals plc's 2007 Equity Incentive Blanch on August 9, 2012. Each restricted stock unit represents a contingent right to receive one ordinary | | | | | | | | | | | | | | | |
| 6. These rest share upon th | ricted stock unine vesting of the | s were granted pursu unit. These units wi | ant to Jazz Pharmace ll vest in full on Augu | uticals p | olc's 200 1 3 / | - 7 Equi (A) | (D) | ntiverPlan on A | Date | Title | stricted stoc Shares k G. Enri | | ents a contingent ri | · | one ordinary |

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.